Ardelyx, Inc. — 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015; the filing also reports unaudited fourth-quarter results. Ardelyx is a clinical-stage biopharmaceutical company with no approved products and no product-sale revenue. Its lead candidate, tenapanor, was in Phase 3 trials for IBS-C and Phase 2b development for hyperphosphatemia in ESRD; RDX022 was in development for hyperkalemia.
Financial performance and liquidity
| Metric | 2015 | 2014 |
|---|---|---|
| Total revenue | $24.0 million | $31.6 million |
| Research and development expense | $39.9 million | $25.9 million |
| General and administrative expense | $13.5 million | $7.3 million |
| Net loss | $29.6 million | $3.2 million |
| Net loss per share, basic and diluted | $1.29 | $0.31 |
| Cash and cash equivalents at year-end | $107.0 million | $107.3 million |
- Revenue comprised $21.6 million of licensing revenue and $2.4 million of collaborative development revenue; none came from product sales. Revenue fell 24% year over year.
- Operating expenses rose 61% to $53.4 million, and operating loss was $29.4 million. The filing does not provide a meaningful product gross margin; the company had no product sales.
- Net cash used in operating activities was $71.8 million, versus $13.4 million provided in 2014. Financing provided $75.0 million, mainly from the June 2015 equity and warrant placement; investing used $3.5 million.
- At year-end, current assets were $112.0 million and current liabilities $7.7 million. Total liabilities were $8.0 million; the filing reports no credit facility or committed capital source. Management said year-end resources plus proceeds from the January 2016 offering were expected to fund operations for at least 12 months, subject to assumptions and changing needs.
- Debt and interest expense are not identified as material in the supplied filing text. Contractual obligations totaled $5.7 million, including $3.3 million of operating leases and $2.3 million of purchase commitments.
- Fourth-quarter 2015 revenue was zero; operating expenses were $16.9 million and net loss was $17.0 million, or $0.65 per share.
Material changes and unusual items
- Ardelyx terminated its tenapanor collaboration with AstraZeneca in June 2015 and regained the NHE3 inhibitor rights. It recognized the remaining $43.1 million deferred revenue balance upon termination, partly offset by $25.0 million in payments to AstraZeneca recorded as a reduction of licensing revenue. The agreement also provides for future payments capped at an aggregate $90 million: 10% royalties on net sales of tenapanor or other NHE3 products and 20% of certain non-royalty collaboration revenue, in addition to the upfront payment.
- The Sanofi NaP2b agreement was terminated effective September 30, 2015, with rights returned to Ardelyx and no termination payment.
- R&D expense increased 54%, reflecting clinical and manufacturing development for tenapanor and RDX022 and $7.3 million of tenapanor clinical-trial material costs from AstraZeneca. G&A rose 86%, largely from professional services, personnel and public-company costs.
- Net loss widened substantially, and accumulated deficit reached $101.5 million. The 2015 result included a second-quarter profit of $9.0 million, primarily reflecting recognition of deferred licensing revenue following the AstraZeneca termination; losses resumed in the third and fourth quarters.
- In June 2015, Ardelyx raised approximately $74.3 million net through an equity and warrant placement. After year-end, its January 2016 public offering raised approximately $80.4 million net, with substantial share dilution.
Outlook, commentary and risks
- Management expected results from the two pivotal tenapanor IBS-C trials in 2017 and results from the tenapanor hyperphosphatemia Phase 2b dosing study in the second half of 2016. The company designed the latter study so that, if positive, the FDA might agree it could count as the first of two well-controlled studies for an NDA; FDA agreement was not assured.
- Management expected to begin an RDX022 Phase 3 program in the second half of 2016 and to file an RDX009 IND in the second half of 2016. These were forward-looking expectations, not guarantees.
- Tenapanor’s earlier IBS-C Phase 2b trial showed efficacy at 50 mg twice daily, but diarrhea was a common adverse event. In the earlier ESRD hyperphosphatemia trial, phosphate reduction was statistically significant and dose-related, while diarrhea and discontinuations due to diarrhea were higher than expected at the highest doses.
- RDX022’s reported January 2016 healthy-volunteer study found it generally well tolerated and showed increased fecal potassium; it did not establish efficacy in hyperkalemia patients. Ardelyx pursued a 505(b)(2) pathway, whose availability and development advantages were uncertain.
- Key risks include clinical-trial failure or delay, safety and tolerability, regulatory approval, manufacturing reliance on third parties, competition, uncertain reimbursement and commercialization capability, intellectual-property challenges, and the need for additional financing. Ardelyx had no products approved, and management expected operating losses to increase as trials advanced.
- The company had no material litigation disclosed. Management reported effective disclosure controls and internal control over financial reporting; the auditor issued an unqualified opinion on the financial statements but did not audit internal controls.
Important facts for investors to verify
- Whether the 2016–2017 clinical milestones were achieved, and whether later trial results support the anticipated indications and regulatory filings.
- The incidence and impact of diarrhea, discontinuations and other safety findings, particularly in the hyperphosphatemia program.
- The full economic effect of the AstraZeneca termination, including the remaining capped payments, royalty obligations and any future collaboration-sharing obligations.
- Cash burn, runway and financing needs after the January 2016 offering, considering trial and manufacturing costs and equity dilution.
- Whether RDX022 can use the 505(b)(2) pathway and demonstrate safety and efficacy in patients, and how competition and reimbursement affect its commercial prospects.